Biotech Values

[rstor1]

ConjuChem Hits Primary End-Point in Monotherapy Phase II Clinical Trial with DAC(TM):GLP-1


http://tinyurl.com/7x2qt

The results look pretty good but they had a large (total 55% of total enrollment) dropout rate. About a third of the dropoute were labeled as "Consent Withdrawal", though. I am not sure what to make of that.

The figures to look at are the "EOD"(3x/wk) and "TW"(2x/wk) efficacy numbers, because this is where CJC's primary advantage over the AMLN product lies.

I am taking the weight-loss numbers with a grain of salt, because of the prevalence of nausea in the study.

The price should come back up, and if it hits ~12US I will try to sell, probably to re-enter once they are on the NAZ

Regards,
Bob